GoodRx (GDRX) Projected to Post Earnings on Wednesday

GoodRx (NASDAQ:GDRX) is projected to post its Q2 2026 results after the market closes on Wednesday, August 5th. Analysts expect GoodRx to post earnings of $0.08 per share and revenue of $193.2310 million for the quarter. Investors may visit the the company’s upcoming Q2 2026 earning results page for the latest details on the call scheduled for Thursday, August 6, 2026 at 8:00 AM ET.

GoodRx (NASDAQ:GDRX) last issued its quarterly earnings data on Wednesday, May 6th. The company reported $0.07 earnings per share (EPS) for the quarter, meeting analysts’ consensus estimates of $0.07. The business had revenue of $194.01 million for the quarter, compared to the consensus estimate of $185.40 million. GoodRx had a return on equity of 7.90% and a net margin of 2.61%.The company’s quarterly revenue was down 4.4% compared to the same quarter last year. During the same period in the prior year, the business posted $0.09 earnings per share. On average, analysts expect GoodRx to post $0 EPS for the current fiscal year and $0 EPS for the next fiscal year.

GoodRx Price Performance

NASDAQ:GDRX opened at $3.16 on Tuesday. The firm has a market capitalization of $1.08 billion, a price-to-earnings ratio of 52.68, a PEG ratio of 1.42 and a beta of 1.60. The company has a debt-to-equity ratio of 0.78, a current ratio of 1.47 and a quick ratio of 1.47. The business has a 50 day simple moving average of $2.90 and a 200-day simple moving average of $2.52. GoodRx has a 1 year low of $1.77 and a 1 year high of $5.81.

Wall Street Analysts Forecast Growth

GDRX has been the topic of several recent research reports. Citigroup restated a “buy” rating on shares of GoodRx in a report on Thursday, July 23rd. TD Cowen boosted their price objective on shares of GoodRx from $3.00 to $4.00 and gave the company a “buy” rating in a research report on Monday, May 11th. Weiss Ratings downgraded shares of GoodRx from a “sell (d+)” rating to a “sell (d)” rating in a research note on Thursday, July 23rd. Finally, The Goldman Sachs Group reissued a “neutral” rating and issued a $3.50 target price on shares of GoodRx in a research note on Friday, May 8th. Five research analysts have rated the stock with a Buy rating, seven have assigned a Hold rating and three have given a Sell rating to the company. Based on data from MarketBeat.com, GoodRx presently has a consensus rating of “Hold” and an average price target of $3.81.

Institutional Investors Weigh In On GoodRx

A number of institutional investors and hedge funds have recently modified their holdings of the business. Quarry LP purchased a new position in GoodRx during the 3rd quarter valued at $33,000. MML Investors Services LLC purchased a new stake in GoodRx in the fourth quarter worth $36,000. DRW Securities LLC bought a new stake in shares of GoodRx during the fourth quarter worth $40,000. Boothbay Fund Management LLC bought a new stake in shares of GoodRx during the third quarter worth $43,000. Finally, EP Wealth Advisors LLC purchased a new stake in shares of GoodRx during the fourth quarter valued at $44,000. 63.77% of the stock is owned by institutional investors.

About GoodRx

GoodRx Holdings, Inc (NASDAQ: GDRX) operates a digital healthcare platform designed to help consumers compare prescription drug prices at retail pharmacies across the United States. Through its website and mobile applications, GoodRx aggregates pricing and discount information from a wide network of pharmacies, enabling users to access coupons and savings programs on both generic and brand-name medications. The platform also features price transparency tools that inform patients about cost variations and available discounts to alleviate the financial burden of prescription medications.

In addition to its core drug pricing service, GoodRx offers telehealth services under the GoodRx Care brand, providing virtual consultations for a range of non-emergency conditions and prescription needs.